BRIEF published on 04/08/2025 at 07:48, 1 year 6 months ago GenSight Biologics dépose son document d'enregistrement universel 2024 Document D'Enregistrement Universel GenSight Biologics Thérapies Géniques Maladies De La Rétine Rapport Financier 2024
PRESS RELEASE published on 04/08/2025 at 07:46, 1 year 6 months ago INFORMATIONS PRIVILÉGIÉES / AUTRES COMMUNIQUÉS GenSight Biologics met à disposition son Document d'Enregistrement Universel 2024 pour consultation en ligne Document D'Enregistrement Universel GenSight Biologics Thérapies Géniques Maladies Neurodégénératives Rétine
PRESS RELEASE published on 04/08/2025 at 07:43, 1 year 6 months ago INSIDE INFORMATION / OTHER NEWS RELEASES GenSight Biologics announces the filing of its 2024 Universal Registration Document with the French market authority, including financial reports and corporate governance details GenSight Biologics Gene Therapies Retinal Neurodegenerative Diseases 2024 Universal Registration Document Central Nervous System Disorders
BRIEF published on 04/07/2025 at 20:19, 1 year 6 months ago GenSight Biologics Financial and Business Update Fundraising Clinical Trials Gene Therapy Financial Update GenSight Biologics
BRIEF published on 04/07/2025 at 20:19, 1 year 6 months ago Mise à jour financière et commerciale de GenSight Biologics Essais Cliniques Thérapie Génique Mise À Jour Financière Collecte De Fonds GenSight Biologics
PRESS RELEASE published on 04/07/2025 at 20:14, 1 year 6 months ago Inside Information / News release on accounts, results GenSight Biologics reports cash position and business update as of March 31, 2025. Discussions with French agency progressing. Fundraising planned for Phase III trial and marketing advancement Business Update Cash Position Fundraising Activities GenSight Biologics RECOVER Phase III Trial
PRESS RELEASE published on 04/07/2025 at 20:14, 1 year 6 months ago Informations privilégiées / Communiqué sur comptes, résultats GenSight Biologics publie sa situation de trésorerie au 31 mars 2025, annonce des activités de levées de fonds pour prolonger l'horizon de trésorerie et fait le point sur ses activités Trésorerie Essai Clinique GenSight Biologics Thérapies Géniques Levées De Fonds
BRIEF published on 03/17/2025 at 07:35, 1 year 7 months ago GenSight Biologics Présente LUMEVOQ® au Congrès NANOS 2025 Thérapie Génique GenSight Biologics LUMEVOQ® NOHL Congrès NANOS
BRIEF published on 03/17/2025 at 07:35, 1 year 7 months ago GenSight Biologics Presents LUMEVOQ® at NANOS 2025 Gene Therapy GenSight Biologics LUMEVOQ® NOHL NANOS Congress
PRESS RELEASE published on 03/17/2025 at 07:30, 1 year 7 months ago Informations privilégiées / Autres communiqués GenSight Biologics annonce des communications scientifiques sur LUMEVOQ® au Congrès 2025 du NANOS. Nouvelles données sur la thérapie génique pour NOHL Thérapie Génique GenSight Biologics NOHL LUMEVOQ NEURO-OPHTALMOLOGIE
Published on 10/29/2026 at 08:00, 22 minutes ago Touchstone Exploration Provides an Operational Update
Published on 10/29/2026 at 07:30, 52 minutes ago Tocvan Pilot Mine Trench at Gran Pilar Averages 4.6 g/t Au With Samples Up to 24.4 g/t Au; New Zone 1.3 km East Returns Up to 234 g/t Ag
Published on 10/28/2026 at 22:35, 9 hours 47 minutes ago Route1 Announces Third Quarter and Year to Date 2026 Financial Results Notification
Published on 10/28/2026 at 12:30, 19 hours 52 minutes ago Digi Power X to Announce 2026 Q3 Financial Results and Provide Operations Update on November 13th
Published on 10/28/2026 at 12:30, 19 hours 52 minutes ago AI/ML Innovations Announces Advance Notice Provisions
Published on 10/29/2026 at 08:00, 21 minutes ago EQS-Adhoc: Henkel AG & Co. KGaA: Henkel achieves very strong organic sales growth in the third quarter and updates outlook for 2026
Published on 10/29/2026 at 08:00, 22 minutes ago Aquis Stock Exchange: Application for admission to trading
Published on 10/29/2026 at 07:20, 1 hour 2 minutes ago Q3 2026: Air Liquide accelerates, driven by sales growth and the launch of its strategic plan
Published on 10/29/2026 at 07:20, 1 hour 2 minutes ago T3 2026 : Air Liquide accélère, porté par des ventes en croissance et le lancement de son plan stratégique
